BRIM-3
2011
Vemurafenib in BRAF V600E-Mutant Metastatic Melanoma
In 675 patients with BRAF V600E-mutant unresectable or metastatic melanoma, vemurafenib improved overall survival compared with dacarbazine.
Result
Efficacy: Co-primary: overall survival and progression-free survival (OS interim analysis)HR 0.37
Below 1 favours vemurafenib, above 1 favours dacarbazine.
Also reported: PFS 5.3 vs 1.6 months (HR 0.26); ORR 48% vs 5%.
- Subtopic
- BRAF-mutant melanoma
- Design
- Open-label RCT
- Relevance
- Supporting: context rather than must-know.
- Source
- Chapman PB, et al. N Engl J Med. 2011;364(26):2507-2516.doi 10.1056/NEJMoa1103782
Discussion & critique
First BRAF inhibitor: proved the precision-oncology principle in melanoma. Resistance emerges quickly; BRAF+MEK combinations (COMBI-d/v) are now preferred.